{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=102",
    "query": {
      "condition": "Multi Center",
      "page": 102
    },
    "page_size": 10
  },
  "pagination": {
    "page": 102,
    "page_size": 10,
    "total_count": 6602,
    "total_pages": 661,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=103&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=101&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T14:14:24.974Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02463344",
      "title": "Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "MA09-hRPE",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Astellas Institute for Regenerative Medicine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-02-25",
      "completion_date": "2019-08-19",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02463344"
    },
    {
      "nct_id": "NCT04696263",
      "title": "Single-Port Versus Multi-Port Robotic Radical Prostatectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Neoplasm of Prostate"
      ],
      "interventions": [
        {
          "name": "Da Vinci ® Xi system - MP Robotic Radical Prostatectomy",
          "type": "DEVICE"
        },
        {
          "name": "Da Vinci ® SP system - SP Robotic Radical Prostatectomy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-01",
      "completion_date": "2025-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04696263"
    },
    {
      "nct_id": "NCT06297993",
      "title": "Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PSC"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "PSC Partners Seeking a Cure",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2000,
      "start_date": "2024-05-06",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06297993"
    },
    {
      "nct_id": "NCT04260152",
      "title": "Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gingival Recession"
      ],
      "interventions": [
        {
          "name": "Geistlich Fibro-Gide",
          "type": "DEVICE"
        },
        {
          "name": "Connective Tissue Graft (CTG",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Geistlich Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-09-01",
      "completion_date": "2020-07-22",
      "has_results": false,
      "last_update_posted_date": "2021-08-10",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 3,
      "location_summary": "Fenton, Michigan • Houston, Texas • Tacoma, Washington",
      "locations": [
        {
          "city": "Fenton",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04260152"
    },
    {
      "nct_id": "NCT04322149",
      "title": "Multiple Doses of AT-1501-A201 in Adults With ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "AT-1501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anelixis Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-10-16",
      "completion_date": "2022-03-24",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Orange, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322149"
    },
    {
      "nct_id": "NCT00103038",
      "title": "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Central Nervous System Lymphoma",
        "Malignant Glioma",
        "Metastatic Malignant Neoplasm in the Brain"
      ],
      "interventions": [
        {
          "name": "3 Tesla Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "MRI-Based Angiogram",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2004-06-04",
      "completion_date": "2016-06-10",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103038"
    },
    {
      "nct_id": "NCT07222215",
      "title": "PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen-receptor-positive Breast Cancer",
        "Metastatic Breast Cancer",
        "Breast Cancer",
        "Hormone Receptor Positive Breast Cancer",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "HER2- Breast Cancer",
        "ESR1 Gene Mutation",
        "ER Wildtype",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Elacestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kristina A. Fanucci",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2026-01-16",
      "completion_date": "2030-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222215"
    },
    {
      "nct_id": "NCT04479436",
      "title": "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Patritumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-09-14",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 21,
      "location_summary": "Fayetteville, Arkansas • Duarte, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04479436"
    },
    {
      "nct_id": "NCT01903187",
      "title": "EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "EnligHTN Renal Denervation",
          "type": "DEVICE"
        },
        {
          "name": "Sham",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2013-10",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 3,
      "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Jackson, Mississippi",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903187"
    },
    {
      "nct_id": "NCT02097147",
      "title": "Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Vilazodone 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Vilazodone 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Paroxetine 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 202,
      "start_date": "2014-03",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2015-02-12",
      "last_synced_at": "2026-11-11T14:14:24.974Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Overland Park, Kansas • Saint Paul, Minnesota + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097147"
    }
  ]
}